Evidence map›Paper›PMID 37881888›Full record

ArticleFEBS open bio2023

Toll-like receptor 9 signaling in chronic lymphocytic leukemia cell lines.

Miriam Meloni, Ilenia Sana, Maria Elena Mantione, Michela Riba, Marta Muzio

Open access · goldAbstract read
In one paragraph

Article in FEBS open bio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Miriam MeloniCell Signaling Unit, Division of Experimental Oncology, San Raffaele Hospital IRCCS, Milan, Italy.
Ilenia SanaCell Signaling Unit, Division of Experimental Oncology, San Raffaele Hospital IRCCS, Milan, Italy.
Maria Elena MantioneCell Signaling Unit, Division of Experimental Oncology, San Raffaele Hospital IRCCS, Milan, Italy.
Michela RibaCenter for Omics Sciences, San Raffaele Hospital IRCCS, Milan, Italy.
Marta MuzioCell Signaling Unit, Division of Experimental Oncology, San Raffaele Hospital IRCCS, Milan, Italy.ORCID 0000-0002-7761-759X
Vita-Salute San Raffaele University · IT

Funding

Associazione Italiana per la Ricerca sul Cancro 23088Ministero della Salute RF-2018-12367072
6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) is a prototypic neoplasia in which malignant cells strongly depend on microenvironmental stimulations in the lymphoid tissues where they accumulate; leukemic cells are exposed to interaction with bystander and accessory cells, as well as inflammatory soluble mediators. Cell lines are frequently used to model the pathobiology of this disease; however, they do not always recapitulate leukemic cell growth and response to stimulation, and no data are available on Toll-like receptors (TLR) signaling in CLL cell lines. To address this gap, we analyzed HG3, MEC2, and PCL12 cell lines, before and after CpG stimulation, by RNA-sequencing followed by bioinformatic analyses and validation experiments. We identified NFKBIZ mRNA and the corresponding IkBz protein as robust markers of TLR9 activation in both MEC2 and PCL12, but not in HG3 cells. Next, we compared our current results with previous results obtained with primary CLL patient samples and were able to conclude that MEC2 is most similar to the patients' cells in terms of global responsiveness to TLR stimulation; in particular, MEC2 better resembles the samples of patients, as it is characterized by high expression levels of IkBz, but with a lower number of genes regulated.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellCell LineHumansSignal TransductionToll-Like Receptor 9Toll-Like ReceptorsTLR9 protein, humanToll-Like Receptor 9Toll-Like Receptorscell linechronic lymphocytic leukemiaCpGNFKBIZToll-like receptor 9

Identifiers

PMID37881888
PMCPMC10699106
OpenAlexW4387950577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.